Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · S

S. 1431 (114th)

Prescription Drug Abuse Prevention and Treatment Act of 2015

referredUnited States· United States Congress· EN

Introduced

21 May 2015

Last action

21 May 2015 · Introduced

Status

Read twice and referred to the Committee on Finance.

Sponsors

Sen. Manchin, Joe, III [D-WV], Sen. King, Angus S., Jr. [I-ME], Sen. Capito, Shelley Moore [R-WV], Sen. McCaskill, Claire [D-MO], Sen. Shaheen, Jeanne [D-NH], Sen. Feinstein, Dianne [D-CA], Sen. Cotton, Tom [R-AR]

Subjects

Healthcare, Education

Source updated

20 January 2026

Healthcare · Education

Summary

Prescription Drug Abuse Prevention and Treatment Act of 2015 This bill amends the Public Health Service Act to require the Substance Abuse and Mental Health Services Administration (SAMHSA) to award grants for consumer education about opioid abuse. (Opioids are drugs with effects similar to opium, such as heroin or certain prescription painkillers.) This bill amends the Controlled Substances Act to require medical practitioners to be trained in the treatment of opioid-dependent patients, pain management, and early detection of opioid addiction before they can be registered by the Drug Enforcement Administration to dispense opioids. Opioid treatment programs that close on any day must make arrangements for each patient to receive treatment during the closure, as necessary. A report must be submitted to SAMHSA for each individual who dies while receiving treatment in an opioid treatment program. In states receiving funding for controlled substance monitoring programs, deaths where an opioid drug is detected in the body must be reported to SAMHSA. The National Center for Health Statistics of the Centers for Disease Control and Prevention must establish a National Opioid Death Registry to track opioid-related deaths. The Agency for Healthcare Research and Quality must develop and apply prescription drug abuse prevention and treatment quality measures. This bill amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to allow prescription drug plan (PDP) sponsors to limit the access of certain beneficiaries to frequently abused drugs. PDP sponsors must have a utilization management tool to prevent drug abuse. Medicare Drug Integrity Contractors may accept prescription and medical records to determine whether a beneficiary is at risk for prescription drug abuse.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 21 May 2015

    Introduced

    Read twice and referred to the Committee on Finance.

    Source: IntroReferral

  2. 21 May 2015

    Introduced

    Introduced in Senate

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in Senate (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate (text)

    Introduced in Senate · EN · 21 May 2015

    ViewDownloadOpen at official source

  • Introduced in Senate (PDF)

    Introduced in Senate · EN · 21 May 2015

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate

    summary · EN · 21 May 2015

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.